Please use this identifier to cite or link to this item:
Title: Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.
Author: Baliakas, Panagiotis
Moysiadis, Theodoros
Hadzidimitriou, Anastasia
Xochelli, Aliki
Jeromin, Sabine
Agathangelidis, Andreas
Mattsson, Mattias
Sutton, Lesley-Ann
Minga, Eva
Scarfò, Lydia
Rossi, Davide
Davis, Zadie
Villamor i Casas, Neus
Parker, Helen
Kotaskova, Jana
Stalika, Evangelia
Plevova, Karla
Mansouri, Larry
Cortese, Diego
Navarro López, Alba
Delgado, Julio (Delgado González)
Larrayoz, Marta
Young, Emma
Anagnostopoulos, Achilles
Smedby, Karin E.
Juliusson, Gunnar
Sheehy, Oonagh
Catherwood, Mark
Strefford, Jonathan C.
Stavroyianni, Niki
Belessi, Chrysoula
Pospisilova, Sarka
Oscier, David
Gaidano, Gianluca
Campo Güerri, Elias
Haferlach, Claudia
Ghia, Paolo
Rosenquist, Richard
Stamatopoulos, Kostas
Keywords: Leucèmia limfocítica crònica
Pronòstic mèdic
Chronic lymphocytic leukemia
Issue Date: Feb-2019
Publisher: Ferrata Storti Foundation
Abstract: Chronic lymphocytic leukemia (CLL) patients with differentialsomatic hypermutation status of the immunoglobulin heavy vari-able genes, namely mutated or unmutated, display fundamentalclinico-biological differences. Considering this, we assessed prognosisseparately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015patients, hypothesizing that the relative significance of relevant indica-tors may differ between these two categories. Within Binet A M-CLLpatients, besides TP53abnormalities, trisomy 12 and stereotyped subset#2 membership were equivalently associated with the shortest time-to-first-treatment and a treatment probability at five and ten years afterdiagnosis of 40% and 55%, respectively; the remaining cases exhibited5-year and 10-year treatment probability of 12% and 25%, respectively.Within Binet A U-CLL patients, besides TP53abnormalities, del(11q)and/or SF3B1mutations were associated with the shortest time-to-first-treatment (5- and 10-year treatment probability: 78% and 98%, respec-tively); in the remaining cases, males had a significantly worse prognosisthan females. In conclusion, the relative weight of indicators that canaccurately risk stratify early-stage CLL patients differs depending on thesomatic hypermutation status of the immunoglobulin heavy variablegenes of each patient. This finding highlights the fact that compartmen-talized approaches based on immunogenetic features are necessary torefine and tailor prognostication in CLL.
Note: Reproducció del document publicat a:
It is part of: Haematologica, 2019, vol. 104, num. 2, p. 360-369
Related resource:
ISSN: 0390-6078
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
682535.pdf1.32 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.